Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 9/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655794 | 0.93 | NPY2R (0.58) | NPY2RALDH1A1GPR119MEN1KMT2A | |
| SCHEMBL22773246 | 0.93 | MEN1 (0.60) | NPY2RALDH1A1GPR119MEN1KMT2A | |
| SCHEMBL22491552 | 0.93 | MEN1 (0.60) | NPY2RALDH1A1GPR119MEN1KMT2A | |
| SCHEMBL16577073 | 0.87 | GPR119 (0.61) | NPY2RGPR119MEN1KMT2AKDM4E | |
| SCHEMBL20602790 | 0.86 | KMT2A (0.56) | NPY2RGPR119MEN1KMT2AKDM4E | |
| SCHEMBL22773288 | 0.86 | RORC (0.55) | NPY2RALDH1A1GPR119KDM4EPKM | |
| SCHEMBL23212017 | 0.85 | NPY2R (0.50) | NPY2RALDH1A1GPR119KDM4EPKM | |
| SCHEMBL30568007 | 0.85 | NPY2R (0.50) | NPY2RALDH1A1GPR119KDM4EPKM | |
| SCHEMBL21752606 | 0.85 | GPR119 (0.59) | NPY2RGPR119MEN1KMT2AKDM4E | |
| SCHEMBL19409663 | 0.85 | GPR119 (0.59) | NPY2RGPR119MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| US-11214578-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214578-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188793-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2021-06-24 | — | — | US | disclosed |
| US-11021453-B2 | Carbamate compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| US-5962476-A | FUNGICIDES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5716969-A | FUNGICIDES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0698606-B1 | AZOLYLAMINE DERIVATIVE | KAKEN PHARMA CO LTD (JP) | 1997-12-17 | — | — | EP | disclosed |
| US-5620994-A | FUNGICIDES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0698606-A1 | AZOLYLAMINE DERIVATIVE | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1996-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530189-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | NPY2R 4661/4885ALDH1A1 2487/4885GPR119 3853/4885 |
| US-11214578-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | FAAH, FAAH2, MGLL | NPY2R 1138/4885ALDH1A1 687/4885GPR119 568/4885 |
| US-11021453-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | NPY2R 4654/4885ALDH1A1 2385/4885GPR119 3935/4885 |
| US-20210188793-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | NPY2R 4661/4885ALDH1A1 2487/4885GPR119 3853/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | NPY2R 4860/4885ALDH1A1 2858/4885GPR119 3832/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | NPY2R 4661/4885ALDH1A1 2487/4885GPR119 3853/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | NPY2R 4860/4885ALDH1A1 2858/4885GPR119 3832/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | NPY2R 4860/4885ALDH1A1 2858/4885GPR119 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.